Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
LONZA LLC currently faces 4 pending office actions in the Biotechnology & Pharmaceuticals sector. These actions are distributed across 4 distinct examiners and 4 distinct art units. The busiest examiner, IVANOVA, SVETLANA M, is assigned to 1 busiest examiner pending office action.
With 4 distinct examiners managing the 4 pending office actions, the portfolio is not concentrated under any individual. This distribution across 4 distinct art units requires a prosecution strategy that addresses multiple technical specializations. The 1 busiest examiner pending action shows that no single examiner currently dominates the company's pending workload. Practitioners must coordinate across the 4 distinct art units to manage the 4 pending office actions effectively.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.5% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| THOMAS, TIMOTHY P | 1 | 26.3% | +38.0% |
| PURDY, KYLE A | 1 | 41.0% | +35.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16310857 | SYNERGISTIC ANTIMICROBIAL COMBINATIONS CONTAINING QUATERNARY AMMONIUM BIOCIDE | THOMAS, TIMOTHY P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041221 | No Rinse Disinfectant with Virucidal Properties Against Non-Enveloped Viruses | IVANOVA, SVETLANA M | 2d overdue |
| 16310857 | SYNERGISTIC ANTIMICROBIAL COMBINATIONS CONTAINING QUATERNARY AMMONIUM BIOCIDE | THOMAS, TIMOTHY P | — |
| 15715371 | Low Residue Disinfecting Wipes | PURDY, KYLE A | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1617 | 1 |
| 1614 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18041221 | No Rinse Disinfectant with Virucidal Properties Against Non-Enveloped Viruses | IVANOVA, SVETLANA M | 1627 | §103 | Final Rejection | 2d overdue | Pending | Feb 10, 2023 |
| 16310871 | SYNERGISTIC COMBINATION OF BIOCIDES | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Final Rejection | 73d overdue | Pending | Dec 18, 2018 |
| 16310857 | SYNERGISTIC ANTIMICROBIAL COMBINATIONS CONTAINING QUATERNARY AMMONIUM BIOCIDE | THOMAS, TIMOTHY P | 1614 | §103 | Final Rejection | — | Pending | Dec 18, 2018 |
| 15715371 | Low Residue Disinfecting Wipes | PURDY, KYLE A | 1611 | §103 | Non-Final OA | — | Pending | Sep 26, 2017 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial